Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant

Transplantation

Volumn 92, Issue 6, 2011, Pages 674-677

  Occhipinti, Margherita ^a   Lampasona, Vito ^b   Vistoli, Fabio ^a   Bazzigaluppi, Elena ^c   Scavini, Marina ^b   Boggi, Ugo ^a   Marchetti, Piero ^a   Bosi, Emanuele ^b,d  

^a CISANELLO HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Laboraf Diagnostica e Ricerca   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Islet autoantibodies; Solitary pancreas transplant; Type 1 diabetes; ZnT8 autoantibodies

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 AUTOANTIBODY; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 AUTOANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; AUTOIMMUNITY; CATION TRANSPORT PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; GRAFT SURVIVAL; HUMANS; IMMUNE SYSTEM; ISLETS OF LANGERHANS; MALE; PANCREAS TRANSPLANTATION; RECURRENCE;

EID: 80052675542     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822ae65f     Document Type: Article

References (24)

1. Gruessner AC, Sutherland DE, Gruessner RW. Pancreas transplantation in the United States: A review. Curr Opin Organ Transplant 2010; 15: 93.
2. Venstrom JM, McBride MA, Rother KI, et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003; 290: 2817.
3. Gruessner RW, Sutherland DE, Kandaswamy R, et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 2008; 85: 42.
4. Sibley RK, Sutherland DE, Goetz F, et al. Recurrent diabetes mellitus in the pancreas iso-and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53: 132.
5. Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol 1987; 128: 151.
6. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008; 118: 1806.
7. Harlan DM, Kenyon NS, Korsgren O, et al. Current advances and travails in islet transplantation. Diabetes 2009; 58: 2175.
8. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in insulin dependent diabetes: Risk assessment strategies yielding high sensitivity. Diabetologia 1995; 38: 816.
9. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53: 384.
10. Orban T, Sosenko JM, Cuthbertson D, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trialtype. Diabetes Care 2009; 32: 2269.
11. Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes 2000; 49: 218.
12. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001; 50: 2464.
13. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104: 17040.
14. Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947.
15. Bosi E, Bottazzo GF, Secchi A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes 1989; 38(suppl 1): 82.
16. Tyden G, Reinholt FP, Sundkvist G, et al. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335: 860.
17. Esmatjes E, Rodriguez-Villar C, Ricart MJ, et al. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation 1998; 66: 128.
18. Jaeger C, BrendelMD,Hering BJ, et al. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibodynegativeIDDMrecipients of intrahepatic islet allografts. Diabetes 1997; 46: 1097.
19. Sundkvist G, Tyden G, Karlsson FA, et al. Islet autoimmunity before and after pancreas transplantation in patients with type 1 diabetes mellitus. Diabetologia 1998; 41: 1532.
20. Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 2000; 69: 99.
21. Skyler JS, Ricordi C. Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes 2011; 60: 1.
22. Boggi U, Amorese G, Marchetti P. Surgical techniques for pancreas transplantation. Curr Opin Organ Transplant 2010; 15: 102.
23. Bonifacio E, Lampasona V, Genovese S, et al. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulindependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995; 155: 5419.
24. Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care 2010; 33: 104.